Alvotech (ALVO) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tarsus Pharmaceuticals (TARS) has outperformed Alvotech (ALVO) over the past year, gaining 3.5% versus a loss of 34.7%. Tarsus Pharmaceuticals is the larger company by market cap ($3.38 billion vs $2.02 billion), about 1.7 times the size. Alvotech converts more of its revenue into profit, with a net margin of 4.8% versus -14.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | TARS |
|---|---|---|
| Share price | $5.67 | $72.22 |
| Market cap | $2.02B | $3.38B |
| 1-day change | -3.08% | -1.89% |
| YTD return | +10.53% | -11.80% |
| 1-year return | -34.68% | +3.54% |
| 5-year return | — | +153.23% |
| Forward P/E | 24.83 | — |
| EPS (TTM) | $-0.62 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $586.32M | $451.36M |
| Revenue growth (YoY) | +19.74% | +146.71% |
| Net income (latest FY) | $27.92M | $-66.42M |
| Gross margin | 59.82% | — |
| Operating margin | 13.34% | -15.72% |
| Net margin | 4.76% | -14.72% |
| 52-week high | $9.05 | $91.53 |
| 52-week low | $2.94 | $53.89 |
| Distance from 52-week high | -37.31% | -21.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +19.93% | +37.77% |
| Average volume | 1.05M | 870.50K |
| Shares outstanding | 356.82M | 46.79M |
| Employees | 1,279 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARS has outperformed ALVO by 38.2 percentage points over the past year.
- Alvotech is more profitable, keeping 4.8 cents of every revenue dollar as net income versus -14.7 cents for Tarsus Pharmaceuticals.
- Tarsus Pharmaceuticals grew revenue faster in its latest fiscal year (+146.71% vs +19.74%).
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
ALVO vs TARS FAQ
Which is bigger, Alvotech or Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.38B compared with $2.02B for Alvotech (ALVO).
Which stock has performed better over the past year, ALVO or TARS?
TARS returned +3.54% over the past 12 months, compared with -34.68% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.